Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Anxiety, Cancer, Cancer, Depression, Depression, Major Depression Disorder (MDD), Psychiatric |
| Therapuetic Areas: | Oncology, Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/17/2019 |
| Start Date: | September 10, 2018 |
| End Date: | December 10, 2021 |
This is a prospective, randomized clinical trial to investigate the clinical impact of a
preemptive pharmacogenomics strategy to guide antidepressant therapy in cancer patients.
Those enrolled onto the clinical trial will be randomized to either DNA-guided choice of
therapy or clinical management alone. Scores on self-reported measures of depressive and
anxiety symptoms along with quality of life will be compared between cohorts.
preemptive pharmacogenomics strategy to guide antidepressant therapy in cancer patients.
Those enrolled onto the clinical trial will be randomized to either DNA-guided choice of
therapy or clinical management alone. Scores on self-reported measures of depressive and
anxiety symptoms along with quality of life will be compared between cohorts.
Inclusion Criteria:
- Patients with a cancer diagnosis
- Be 18 years of age or older
- Patients who rate depression or anxiety > 5 based on a 10 point scale
- Patients expected to live greater than 6 months
- Serum bilirubin and creatinine < 1.5x upper limit of normal
- AST and ALT < 3 times upper limit of normal
- Willing and able to provide written informed consent
- Able to complete self-assessment questionnaires
Exclusion Criteria:
- Patients not diagnosed with cancer
- Antidepressant prescribing performed by a non-Moffitt psychiatrist after enrollment
onto the clinical trial
- Known Pregnancy
- History of liver or allogenic stem cell transplant
- Patients with a known cognitive impairment (e.g., delirium, dementia, etc.) or
psychological impairment (e.g., schizophrenia, bipolar disease, etc.) other than
depressive and anxiety symptoms.
We found this trial at
1
site
12902 USF Magnolia Dr
Tampa, Florida 33612
Tampa, Florida 33612
(888) 663-3488
Principal Investigator: James K Hicks, PharmD, PhD
Phone: 813-745-4668
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
Click here to add this to my saved trials
